Levetiracetam in the Management of Bipolar Depression

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by Yale University.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Stanley Medical Research Institute
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
NCT00566150
First received: November 29, 2007
Last updated: July 31, 2008
Last verified: July 2008

November 29, 2007
July 31, 2008
October 2005
October 2008   (final data collection date for primary outcome measure)
Change in depressive symptom scores from baseline. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00566150 on ClinicalTrials.gov Archive Site
  • Change in depressive symptom scores from baseline. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Number of subjects who achieve remission. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Change in ratings on the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP). [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Levetiracetam in the Management of Bipolar Depression
Levetiracetam in the Management of Bipolar Depression

A 6-week outpatient, double-blind, placebo-controlled, add-on trial to investigate the effects of levetiracetam on depressive symptoms in bipolar depressed patients.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Bipolar Depression
  • Drug: Levetiracetam
    Flexible dose up to 2500mg per day, for 6 weeks.
    Other Name: Keppra
  • Drug: Placebo
    Flexible dose up to 2500mg per day, for 6 weeks.
  • Active Comparator: A
    Intervention: Drug: Levetiracetam
  • Placebo Comparator: P
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
50
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • DSM-IV diagnosis of bipolar disorder
  • Presence of a current major depressive episode on the SCID
  • Score of 17 or great on the HDRS
  • Capable of giving voluntary written consent

Exclusion Criteria:

  • Significant current substance dependence/abuse within 3 months preceding the trial
  • Active suicidal ideation
  • Pregnant/lactating mothers
  • Significant medical history
Both
18 Years to 65 Years
No
Contact: Kathleen Maloney, BA 203-974-7496 kathleen.maloney@yale.edu
Contact: Jason Chen, BA 203-974-7559 jason.chen.jc64@yale.edu
United States
 
NCT00566150
05T-681, HIC#0508000506
No
Zubin Bhagwagar, Yale University
Yale University
Stanley Medical Research Institute
Principal Investigator: Zubin Bhagwagar, MD PhD Yale University
Yale University
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP